CCDC 1982338: Experimental Crystal Structure Determination
Pei‐Pei Kung(Pfizer (United States)), Martin A. Edwards(University of Utah), Alexei Brooun(Pfizer (United States)), Lisa Nguyen(Pfizer (United States)), Penney Khamphavong(Pfizer (United States)), K.S. Gajiwala(Pfizer (United States)), Luke R. Zehnder(University of Minnesota), Huichun Zhu(Pfizer (United States)), Robert S. Kania(RG Biopharma (United States)), Michael R. Collins(Pfizer (United States)), Manfred Kraus(Harvard University), Shikhar Sharma(Pfizer (United States)), Shuibo Xin(WuXi AppTec (China)), Patrick Bingham(Pfizer (United States)), Shinji Yamazaki, Shuiwang Wang(WuXi AppTec (China)), Susan E. Kephart(Pfizer (United States)), Robert A. Kumpf(Pfizer (United States)), Neal W. Sach(Pfizer (United States)), Jillian E. Spangler(Scripps Research Institute), Martin Wythes(Pfizer (United States)), Hovhannes J. Gukasyan(Pfizer (United States)), Karen A. Maegley(Pfizer (United States)), Wenyue Hu(Beijing University of Chinese Medicine), Dominique Verhelle(Pfizer (United States)), S. Scott Sutton, Sean Uryu(Pfizer (United States)), Dan Richter(Pfizer (United States)), Cody Krivacic(Pfizer (United States)), Hui Wang(Ministry of Education), JinJiang Zhu(Pfizer (United States)), Wei Liu, Dac M. Dinh(Pfizer (United States)), Albert Stewart(Pfizer (United States)), Shijian Ren(WuXi AppTec (China)), John Sherrill(Pfizer (United States)), Robert A. Rollins(Pfizer (United States)), Rita Grantner(Pfizer (United States)), Buwen Huang(Pfizer (United States)), Connie Fan(Pfizer (United States))
Cited by 0
Related Papers
Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
|Journal of Medicinal Chemistry|2011|924
Ligand-Controlled C(sp <sup>3</sup> )–H Arylation and Olefination in Synthesis of Unnatural Chiral α–Amino Acids
|Science|2014|501